ECCOGENE Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 55

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 13

ECCOGENE General Information

Description

Developer of metabolism and immune-related diseases intended to treat obesity and diabetes. The company specializes in disease biology, medicinal chemistry, and translational science and aims to create molecular level immunological pharmaceuticals to treat complex chronic diseases, providing a pipeline of metabolic drugs to improve patient conditions.

Contact Information

Website
www.eccogene.com
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 402A, No. 326 Edison Road
  • Zhangjiang Hi-Tech Park, Pudong New Area
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Room 402A, No. 326 Edison Road
  • Zhangjiang Hi-Tech Park, Pudong New Area
  • Shanghai, 201203
  • China
+86 021

ECCOGENE Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ECCOGENE Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. IPO 15-Oct-2025 Announced Clinical Trials - General
10. Secondary Transaction - Private 22-Apr-2025 Completed Clinical Trials - General
9. Secondary Transaction - Private 31-Dec-2024 Completed Clinical Trials - General
8. Secondary Transaction - Private 11-Jun-2024 Completed Clinical Trials - General
7. Secondary Transaction - Private 24-Jan-2025 Completed Clinical Trials - General
6. Secondary Transaction - Private 24-Jan-2024 Completed Clinical Trials - General
5. Secondary Transaction - Private 08-Jan-2024 Completed Clinical Trials - General
4. Later Stage VC (Series C) 20-Dec-2023 Completed Clinical Trials - General
3. Later Stage VC (Series B) 11-Jun-2023 $25.5M $59.9M Completed Clinical Trials - General
2. Early Stage VC (Series A1) 22-Dec-2020 $19.8M $34.4M Completed Clinical Trials - General
To view ECCOGENE’s complete valuation and funding history, request access »

ECCOGENE Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of metabolism and immune-related diseases intended to treat obesity and diabetes. The company specializes in d
Drug Discovery
Shanghai, China
55 As of 2025

Hong Kong, Hong Kong
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ECCOGENE Competitors (1)

One of ECCOGENE’s competitors is HUTCHMED, a Corporation company based in Hong Kong, Hong Kong.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
HUTCHMED Corporation Hong Kong, Hong Kong
You’re viewing 1 of 1 competitors. Get the full list »

ECCOGENE Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

ECCOGENE Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022199661-A1 Phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-phenyl-, phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-heteroaryl-, or phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo [d] imidazole-carboxylic acid derivatives and methods of using same Inactive 24-Mar-2021
US-20220348564-A1 Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same Inactive 24-Mar-2021
WO-2022017338-A1 Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same Inactive 20-Jul-2020
WO-2021143706-A1 Substituted triazinones as thyroid hormone receptor agonists Inactive 13-Jan-2020
WO-2021083209-A1 Ssao inhibitors and use thereof Inactive 29-Oct-2019 C07D319/12
To view ECCOGENE’s complete patent history, request access »

ECCOGENE Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ECCOGENE Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
CICC Private Equity Corporate Venture Capital Minority
Sage Partners (Hong Kong) Hedge Fund Minority
AstraZeneca Corporation Minority
Elikon Venture Growth/Expansion Minority
Huajin Investment Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

ECCOGENE FAQs

  • When was ECCOGENE founded?

    ECCOGENE was founded in 2018.

  • Where is ECCOGENE headquartered?

    ECCOGENE is headquartered in Shanghai, China.

  • What is the size of ECCOGENE?

    ECCOGENE has 55 total employees.

  • What industry is ECCOGENE in?

    ECCOGENE’s primary industry is Drug Discovery.

  • Is ECCOGENE a private or public company?

    ECCOGENE is a Private company.

  • What is ECCOGENE’s current revenue?

    The current revenue for ECCOGENE is .

  • How much funding has ECCOGENE raised over time?

    ECCOGENE has raised $84.9M.

  • Who are ECCOGENE’s investors?

    CICC Private Equity, Sage Partners (Hong Kong), AstraZeneca, Elikon Venture, and Huajin Investment are 5 of 13 investors who have invested in ECCOGENE.

  • Who are ECCOGENE’s competitors?

    HUTCHMED is a competitor of ECCOGENE.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process